Case studies

Example 1

Evaluation of cardiovascular effects reported in pivotal toxicology studies.

Initial findings in the safety pharmacology studies suggested a CV effect, an independent review of the ECGs from the pivotal toxicology study provided additional reassurance to progress the candidate drug in clinical development

Example 2

Due diligence data review.

In preparation for out-licensing Pharm Tox Consulting were engaged to review the current data package and conduct a gap-analysis on the pharmacology data. Secondly, to prepare a non-clinical development strategy - detailing study outline costs and timelines.